Stable transfection pools for large quantity of protein production.
During the early development phase of therapeutic proteins such as monoclonal antibodies, representative material is often requested before the final production cell line is established. In order to fulfill such requests, technologies capable of delivering large quantity of proteins quickly are essential. This chapter outlines the stable transfection pool technology that generates grams of proteins within 2 months post transfection. This technology shortens the overall developmental time frame for therapeutic proteins.
Bioprocess Research & Development, Merck & Co., Inc, Rahway, NJ, USA. Jianxin_Ye@merck.com
Jianxin
J
Ye
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D016466:CHO Cells / Q000166:cytology; D006224:Cricetinae; D005822:Genetic Vectors; D006031:Glycosylation; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D014162:Transfection / Q000379:methods*
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D011994:Recombinant Proteins